Baidu
map

Nat Commun:BMI1在前列腺癌中可以调控雄激素受体且不受多梳抑制复合物1影响

2018-02-27 AlexYang MedSci原创

BMI1是一个多梳家族(PcG)蛋白成员,在细胞分化和增殖表观遗传调控方面具有重要的作用,同时,在癌症干细胞自我更新方面也具有重要作用。之前的研究表明,BMI1在多种癌症中表达上调,包括了前列腺癌,作为多梳蛋白复合物1(PRC1)的关键组成成分,BMI1可以通过增强RING1B的酶活性在赖氨酸119位点泛素化组蛋白H2A,从而来表现其致癌功能,并且还抑制了基因的转录。最近,有研究人员报道了BMI1

BMI1是一个多梳家族(PcG)蛋白成员,在细胞分化和增殖表观遗传调控方面具有重要的作用,同时,在癌症干细胞自我更新方面也具有重要作用。

之前的研究表明,BMI1在多种癌症中表达上调,包括了前列腺癌,作为多梳蛋白复合物1(PRC1)的关键组成成分,BMI1可以通过增强RING1B的酶活性在赖氨酸119位点泛素化组蛋白H2A,从而来表现其致癌功能,并且还抑制了基因的转录。最近,有研究人员报道了BMI1独立于PRC1的作用对去势难治性前列腺癌(CRPC)的恶化是非常重要的。研究发现,BMI1可以结合雄激素受体(AR)和阻止MDM2调控的AR蛋白降解,从而进一步导致了前列腺癌细胞中AR信号的持续存在。更重要的是,研究人员阐释了以BMI1为靶标可以有效的抑制异种种植模型中肿瘤的生长,这些异种种植模型已经对手术去势和恩杂鲁胺治疗产生了抗性。

最后,研究人员指出,这些结果表明了单独阻断BMI1的功能或者结合AR抗肿瘤治疗能够更有效的抑制肿瘤生长。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1882871, encodeId=07fa18828e106, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Aug 24 04:57:00 CST 2018, time=2018-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087290, encodeId=59dd208e290e1, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Fri May 04 05:57:00 CST 2018, time=2018-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=306853, encodeId=ce24306853a0, content=了解一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Wed Apr 18 07:05:13 CST 2018, time=2018-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1910610, encodeId=f7fa19106105c, content=<a href='/topic/show?id=b45b426195e' target=_blank style='color:#2F92EE;'>#复合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42619, encryptionId=b45b426195e, topicName=复合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad7f282, createdName=yang0210, createdTime=Thu Jan 10 23:57:00 CST 2019, time=2019-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350531, encodeId=70a5135053145, content=<a href='/topic/show?id=a7689869104' target=_blank style='color:#2F92EE;'>#雄激素受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98691, encryptionId=a7689869104, topicName=雄激素受体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Mar 01 12:57:00 CST 2018, time=2018-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=291744, encodeId=ad94291e448e, content=学习了.有用.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/17/cfa76f1048392033b44c71e9bcb628d9.jpg, createdBy=096c2156900, createdName=梦想起航ing, createdTime=Wed Feb 28 17:09:34 CST 2018, time=2018-02-28, status=1, ipAttribution=)]
    2018-08-24 liye789132251
  2. [GetPortalCommentsPageByObjectIdResponse(id=1882871, encodeId=07fa18828e106, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Aug 24 04:57:00 CST 2018, time=2018-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087290, encodeId=59dd208e290e1, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Fri May 04 05:57:00 CST 2018, time=2018-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=306853, encodeId=ce24306853a0, content=了解一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Wed Apr 18 07:05:13 CST 2018, time=2018-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1910610, encodeId=f7fa19106105c, content=<a href='/topic/show?id=b45b426195e' target=_blank style='color:#2F92EE;'>#复合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42619, encryptionId=b45b426195e, topicName=复合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad7f282, createdName=yang0210, createdTime=Thu Jan 10 23:57:00 CST 2019, time=2019-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350531, encodeId=70a5135053145, content=<a href='/topic/show?id=a7689869104' target=_blank style='color:#2F92EE;'>#雄激素受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98691, encryptionId=a7689869104, topicName=雄激素受体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Mar 01 12:57:00 CST 2018, time=2018-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=291744, encodeId=ad94291e448e, content=学习了.有用.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/17/cfa76f1048392033b44c71e9bcb628d9.jpg, createdBy=096c2156900, createdName=梦想起航ing, createdTime=Wed Feb 28 17:09:34 CST 2018, time=2018-02-28, status=1, ipAttribution=)]
    2018-05-04 liuli5079
  3. [GetPortalCommentsPageByObjectIdResponse(id=1882871, encodeId=07fa18828e106, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Aug 24 04:57:00 CST 2018, time=2018-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087290, encodeId=59dd208e290e1, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Fri May 04 05:57:00 CST 2018, time=2018-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=306853, encodeId=ce24306853a0, content=了解一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Wed Apr 18 07:05:13 CST 2018, time=2018-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1910610, encodeId=f7fa19106105c, content=<a href='/topic/show?id=b45b426195e' target=_blank style='color:#2F92EE;'>#复合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42619, encryptionId=b45b426195e, topicName=复合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad7f282, createdName=yang0210, createdTime=Thu Jan 10 23:57:00 CST 2019, time=2019-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350531, encodeId=70a5135053145, content=<a href='/topic/show?id=a7689869104' target=_blank style='color:#2F92EE;'>#雄激素受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98691, encryptionId=a7689869104, topicName=雄激素受体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Mar 01 12:57:00 CST 2018, time=2018-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=291744, encodeId=ad94291e448e, content=学习了.有用.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/17/cfa76f1048392033b44c71e9bcb628d9.jpg, createdBy=096c2156900, createdName=梦想起航ing, createdTime=Wed Feb 28 17:09:34 CST 2018, time=2018-02-28, status=1, ipAttribution=)]
    2018-04-18 kafei

    了解一下谢谢

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1882871, encodeId=07fa18828e106, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Aug 24 04:57:00 CST 2018, time=2018-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087290, encodeId=59dd208e290e1, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Fri May 04 05:57:00 CST 2018, time=2018-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=306853, encodeId=ce24306853a0, content=了解一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Wed Apr 18 07:05:13 CST 2018, time=2018-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1910610, encodeId=f7fa19106105c, content=<a href='/topic/show?id=b45b426195e' target=_blank style='color:#2F92EE;'>#复合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42619, encryptionId=b45b426195e, topicName=复合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad7f282, createdName=yang0210, createdTime=Thu Jan 10 23:57:00 CST 2019, time=2019-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350531, encodeId=70a5135053145, content=<a href='/topic/show?id=a7689869104' target=_blank style='color:#2F92EE;'>#雄激素受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98691, encryptionId=a7689869104, topicName=雄激素受体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Mar 01 12:57:00 CST 2018, time=2018-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=291744, encodeId=ad94291e448e, content=学习了.有用.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/17/cfa76f1048392033b44c71e9bcb628d9.jpg, createdBy=096c2156900, createdName=梦想起航ing, createdTime=Wed Feb 28 17:09:34 CST 2018, time=2018-02-28, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1882871, encodeId=07fa18828e106, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Aug 24 04:57:00 CST 2018, time=2018-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087290, encodeId=59dd208e290e1, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Fri May 04 05:57:00 CST 2018, time=2018-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=306853, encodeId=ce24306853a0, content=了解一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Wed Apr 18 07:05:13 CST 2018, time=2018-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1910610, encodeId=f7fa19106105c, content=<a href='/topic/show?id=b45b426195e' target=_blank style='color:#2F92EE;'>#复合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42619, encryptionId=b45b426195e, topicName=复合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad7f282, createdName=yang0210, createdTime=Thu Jan 10 23:57:00 CST 2019, time=2019-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350531, encodeId=70a5135053145, content=<a href='/topic/show?id=a7689869104' target=_blank style='color:#2F92EE;'>#雄激素受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98691, encryptionId=a7689869104, topicName=雄激素受体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Mar 01 12:57:00 CST 2018, time=2018-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=291744, encodeId=ad94291e448e, content=学习了.有用.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/17/cfa76f1048392033b44c71e9bcb628d9.jpg, createdBy=096c2156900, createdName=梦想起航ing, createdTime=Wed Feb 28 17:09:34 CST 2018, time=2018-02-28, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1882871, encodeId=07fa18828e106, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Aug 24 04:57:00 CST 2018, time=2018-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087290, encodeId=59dd208e290e1, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Fri May 04 05:57:00 CST 2018, time=2018-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=306853, encodeId=ce24306853a0, content=了解一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Wed Apr 18 07:05:13 CST 2018, time=2018-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1910610, encodeId=f7fa19106105c, content=<a href='/topic/show?id=b45b426195e' target=_blank style='color:#2F92EE;'>#复合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42619, encryptionId=b45b426195e, topicName=复合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad7f282, createdName=yang0210, createdTime=Thu Jan 10 23:57:00 CST 2019, time=2019-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350531, encodeId=70a5135053145, content=<a href='/topic/show?id=a7689869104' target=_blank style='color:#2F92EE;'>#雄激素受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98691, encryptionId=a7689869104, topicName=雄激素受体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Mar 01 12:57:00 CST 2018, time=2018-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=291744, encodeId=ad94291e448e, content=学习了.有用.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/17/cfa76f1048392033b44c71e9bcb628d9.jpg, createdBy=096c2156900, createdName=梦想起航ing, createdTime=Wed Feb 28 17:09:34 CST 2018, time=2018-02-28, status=1, ipAttribution=)]
    2018-02-28 梦想起航ing

    学习了.有用.谢谢分享

    0

相关资讯

Sci Rep:前列腺癌中,ITGB1依赖的小窝蛋白-1上调可以使TGFβ信号从肿瘤抑制到致瘤的变化

小窝蛋白-1(CAV-1)在前列腺癌(PCa)中是过表达的,并且与不良的预后相关,但是CAV1表达到疾病恶化之间的分子机制仍旧所知甚少。最近,有研究人员利用大规模基因表达相关性分析、临床样本的定量多通道成像以及CAV1依赖的转录组分析,支持了CAV1可以使得TGFβ信号从肿瘤抑制到致瘤的转变(比如SLUG、PAI-1的诱导和CDH1、DSP和CDKN1A的抑制)。还支持了CAV1的敲除能都导致前列

CLIN CANCER RES:恩杂鲁胺对卡巴他赛药代动力学的影响

在转移性去势抵抗前列腺癌的临床研究中,目前正在探索紫杉烷类联合AR靶向药物,即恩杂鲁胺和阿比特龙的治疗效果是否可以得到增强。因为恩杂鲁胺可以诱导CYP3A4酶而紫杉烷类药物由这种酶代谢,需要研究其潜在的药物之间的相互作用。CLIN CANCER RES近期发表了一篇文章研究这一问题。

Sci Rep:利用数学模拟的前列腺癌个性化抑制研究

最近,有研究人员利用150名病人通过一个固定的治疗计划进行的间歇性雄激素抑制(IAS)治疗的数据,为每一位病人回顾性的设计了一个个性化的治疗计划。考虑到了前列腺特异性抗原(PSA)的不确定性,研究人员通过对每位病人的时间点采取随机重复取样的方法为每一位病人评估了100套参数值。之后,研究人员鉴定了3种类型并且根据以下3种类型鉴定分类:类型1:复发,即PSA的散度,可以通过IAS来抑制;类型2:复发

Urol J:患有前列腺癌且经历雄激素阻断治疗的病人中抑郁与许多风险因素之间的相关性分析

最近,有研究人员在经历雄激素阻断疗法(ADT)治疗前列腺癌的患者中鉴定了影响抑郁的因素。研究包括了那些拜访精神病门诊的患有前列腺癌的患者,并且他们都经历了ADT且伴随着抑郁症状。为了评估抑郁症状,研究人员使用了白氏抑郁症量表(BDI)。为了鉴定影响抑郁症的风险因素,研究人员进行了单变量和多变量的线性回归分析。研究发现,参与者(n=45)的平均年龄、ADT起始治疗年龄和ADT持续时间、血清睾丸素水平

CLIN CANCER RES:阻断神经内分泌分化和巨噬细胞反馈回路可以改善恩杂鲁胺对前列腺癌治疗效果

去势治疗(ADT)会导致前列腺癌产生耐药。ADT耐药与神经内分泌分化和肿瘤相关巨噬细胞有关。CLIN CANCER RES近期发表了一篇文章,研究恩杂鲁胺诱导的神经内分泌分化和肿瘤相关巨噬细胞及其机制。

Sci Rep:在前列腺癌细胞中,白花丹素诱导的差异基因表达受雄激素受体调控

小鼠获得性前列腺PTEN-P2肿瘤或者体内前列腺组织的 5-hydroxy-2-methyl-1,4-naphth oquinone(白花丹素)处理能够在去势小鼠中导致肿瘤退化,但是在完整的小鼠中没有上述情况。这表明了由于白花丹素处理,双氢睾酮(DHT)在这些睾丸中的产生也许阻止了细胞的死亡,但是潜在的机制仍旧不清楚。最近,有研究人员在白花丹素和DHT组合处理的细胞中进行了RNA-seq测序分析,

Baidu
map
Baidu
map
Baidu
map